This previous process, which prioritised the need to secure broad industry support for reforms, has been displaced by a system of layered privilege. This is partly due to the government's more aggressive and impatient approaches to reform and partly because the industry has become more acquiescent.
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Priceline moves to stabilise banner group as pressures force administrators
December 17, 2025 - - Latest News -
Rare Cancers Australia gearing up for 2026 Kosi Challenge with Pharma Cup up for grabs again
December 17, 2025 - - Latest News -
Ferronova secures funding to advance nanoparticle technology for cancer surgery
December 17, 2025 - - Australian Biotech -
Antimalarial candidate under WEHI-MSD partnership offers fresh hope against resistance
December 17, 2025 - - Latest News -
OncoSil completes first production run at new Sydney manufacturing facility
December 17, 2025 - - Australian Biotech -
Budget update repeats the 'fiscal illusion' that has become PBS spending
December 17, 2025 - - Latest News -
Island Pharmaceuticals secures key partnership with Texas Biomed
December 17, 2025 - - Australian Biotech

